Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy

Documenti analoghi

• Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
  di: Wardell, Suzanne E., et al.
  Pubblicazione: (2019)
• The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
  di: Wardell, Suzanne E., et al.
  Pubblicazione: (2011)
• Targeting mutant estrogen receptors
  di: Wardell, Suzanne E, et al.
  Pubblicazione: (2019)
• Oral selective estrogen receptor downregulators (SERDs) a breakthrough endocrine therapy for breast cancer
  di: McDonnell, Donald P., et al.
  Pubblicazione: (2015)
• Estrogen Down-regulator Fulvestrant Potentiates Antitumor Activity of Fluoropyrimidine in Estrogen-responsive MCF-7 Human Breast Cancer Cells
  di: NUKATSUKA, MAMORU, et al.
  Pubblicazione: (2019)